Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2021 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The question asks: does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to check the transcript for management's forward-looking statements. The call includes Rob Fried (CEO), Andrew Shao (SVP), Kevin Farr (CFO). They discuss various partners: Sinopharm, H&H Group, Ro, Nestle, Designs for Health, Watsons, Monte Cana, etc. They talk about these partners' plans, launches, rollouts, etc. For example, Sinopharm: "We're finalizing the commercial plans and the supply agreement Sinopharm for initial cross-border sales, as well as our approach to pursuing Blue Hat approval in parallel." That suggests they are still finalizing, not yet supplying. H&H: "While our expectation is that H&H will not launch in the first quarter of 2022 as previously communicated, our R&D team continues to work closely with H&H on the new product formulation. H&H remains excited about the potential of Niagen." That indicates H&H hasn't launched yet. Designs for Health: "They will offer specifically formulated products with Niagen exclusively to these HCPs." That is a new partnership, but not yet launched. Nestle: "we are in discussions about how to make the partnerships more impactful over time." That is not a current trajectory. The question asks if management's forward account consists of reporting on the growth, expansion, ramp, adoption, or program build-out of specific counterparties that the company ALREADY SUPPLIES OR SERVES. That means the company is already supplying them, and their growth is driving the company's future. For example, Watsons: they have sales, but they are facing COVID headwinds. Monte Cana: sales impacted by COVID. Those are not early and large relative to the company; they are struggling. The key is whether management describes counterparties' own trajectories as early and large, and the company is already inside that growth.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.